BDBM107719 US11426393, Compound Table XV.25::US8598210, Table XV, 25::US8722895, 25: ({5-[3-(cyclopropanecarbonyl-amino)- phenyl]-3-hydroxy-pyridine-2-carbonyl}- amino)-acetic acid methyl ester::US9598370, Example 00150::USRE47437, Example ({5-[3-(Cyclopropanecarbonyl-amino)-phenyl]-3-hydroxy-pyridine-2-carbonyl}-amino)-acetic acid methyl ester

SMILES COC(=O)CNC(=O)c1ncc(cc1O)-c1cccc(NC(=O)C2CC2)c1

InChI Key InChIKey=NJTATWKWAORKQP-UHFFFAOYSA-N

Data  5 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 5 hits for monomerid = 107719   

TargetEgl nine homolog 1(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107719(US8722895, 25: ({5-[3-(cyclopropanecarbonyl-amino)...)
Affinity DataIC50: 9.20E+3nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2014
Entry Details
Go to US Patent

TargetEgl nine homolog 1(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107719(US8722895, 25: ({5-[3-(cyclopropanecarbonyl-amino)...)
Affinity DataIC50: 9.20E+3nMT: 2°CAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2014
Entry Details
Go to US Patent

TargetEgl nine homolog 1(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107719(US8722895, 25: ({5-[3-(cyclopropanecarbonyl-amino)...)
Affinity DataIC50: 9.20E+3nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
Go to US Patent

TargetEgl nine homolog 1(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107719(US8722895, 25: ({5-[3-(cyclopropanecarbonyl-amino)...)
Affinity DataIC50: 9.20E+3nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
US Patent

TargetEgl nine homolog 1 [179-426](Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107719(US8722895, 25: ({5-[3-(cyclopropanecarbonyl-amino)...)
Affinity DataIC50: 9.20E+3nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent